Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.48 |
| ▸ | TTPA | P49638 | 2/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 11/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14948992 | 0.91 | PSEN1 (0.56) | PTPN1GSTO1TTPAALOX5PSEN1 | |
| SCHEMBL14948984 | 0.91 | PSEN1 (0.56) | PTPN1GSTO1TTPAALOX5PSEN1 | |
| SCHEMBL16247634 | 0.89 | PTPN1 (0.58) | PTPN1GSTO1TTPAALOX5PSEN1 | |
| SCHEMBL16247646 | 0.82 | PSEN1 (0.56) | PTPN1GSTO1TTPAALOX5PSEN1 | |
| SCHEMBL16247641 | 0.82 | PSEN1 (0.56) | PTPN1GSTO1TTPAALOX5PSEN1 | |
| SCHEMBL14950745 | 0.82 | TTPA (0.54) | PTPN1GSTO1TTPAALOX5PSEN1 | |
| SCHEMBL16247656 | 0.82 | PSEN1 (0.52) | PTPN1GSTO1TTPAPSEN1 | |
| SCHEMBL14948991 | 0.81 | PTPN1 (0.59) | PTPN1GSTO1TTPAALOX5PSEN1 | |
| SCHEMBL14948986 | 0.81 | PTPN1 (0.59) | PTPN1GSTO1TTPAALOX5PSEN1 | |
| SCHEMBL14950826 | 0.79 | PTPN1 (0.57) | PTPN1GSTO1TTPAALOX5PSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206192-B2 | Trolox derivative-modified fat-soluble anti-cancer pharmaceutical compounds, preparations, preparing methods and use thereof | Jiangsu Chiatei Tianqing Pharmaceutical Co., LTd (CN) | 2015-12-08 | — | — | US | disclosed |
| US-20140343088-A1 | TROLOX DERIVATIVE-MODIFIED FAT-SOLUBLE ANTI-CANCER PHARMACEUTICAL COMPOUNDS, PREPARATIONS, PREPARING METHODS AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343088-A1 | TROLOX DERIVATIVE-MODIFIED FAT-SOLUBLE ANTI-CANCER PHARMACEUTICAL COMPOUNDS, PREPARATIONS, PREPARING METHODS AND USE THEREOF | TTPA, PLIN1, PLIN5 | PTPN1 3709/4885GSTO1 59/4885TTPA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.